Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80190 |
Name | malignant epithelioid hemangioendothelioma |
Definition | A malignant hemangioma characterized by the presence of epithelioid endothelial cells. The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer malignant hemangioma malignant epithelioid hemangioendothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH2 V305M | Olaparib | malignant epithelioid hemangioendothelioma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Completed | ITA | GBR | ESP | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04857372 | Phase I | IAG933 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Terminated | USA | GBR | AUS | 0 |
NCT06452160 | Phase I | BGC515 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |